To sign up for our free research reports and newsletters, visit http://BeaconEquityResearch.com. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Detailed quote: http://beaconequityresearch.com/AAGH
December 17, 2007 -
Asia Global Holdings Corporation (OTC Bulletin Board: AAGH) has announced that management account results for the month of October and November, year 2007 show the two months revenues from its media & advertising business segment at approximately $3,009,195, already well surpassed last year's quarterly figure of $1,580,663. When compared to the revenue of same two-month period of last year, $1,220,434, this year's figure represents a growth of 146.6%. These results validate that the company's media & advertising segment continues to demonstrate sizable and sustainable growth.
Beginning with the third quarter the Company changed its financial segmentation moving all TV entertainment related business, conducted by its subsidiary China Media Power, from its "Media & Advertising" segment into a segment titled "TV Entertainment." The longer-standing non-broadcast media and advertising business remain in the "Media & Advertising" segment.
Spicy Pickle (OTCBB: SPKL) Up 16.22% on Monday
Detailed quote: http://beaconequityresearch.com/SPKL
December 17, 2007 - Spicy Pickle(R) Announces New 10 Store Franchise Agreement in
Spicy Pickle� fast casual restaurants (OTCBB: SPKL) today announced the sale of a multi unit restaurant development to a new franchise developer in
A new franchisee with extensive restaurant experience has entered into a franchise and development agreement to open the first Spicy Pickle� Restaurants in western
Marc Geman, CEO of Spicy Pickle� Franchising, Inc., commented: "We are thrilled to have our first franchisee in the state of
Mr. Geman further commented, "Much like our very successful Boulder, Colorado and Austin, Texas locations, the Ann Arbor and E. Lansing areas offer a similar demographic with a high concentration of University, Medical, and Research facilities. There is also a similar concentration in
Voyant International Corporation (OTCBB: VOYT) Up 12.50% on Monday
Detailed quote: http://beaconequityresearch.com/VOYT
December 17, 2007 - Voyant Management Exchanges Debt for Equity Investment in Company
Voyant International Corporation (OTCBB: VOYT), a diversified media and technology holding company dedicated to improving the quality of the digital world for both businesses and consumers, announced that its senior management team has converted a significant portion of deferred pay and company debt into convertible preferred stock. All six members of Voyant's senior management team have signed definitive agreements for this conversion, as detailed in the company's 8-K SEC filing dated Dec. 13, 2007.
"All of the members of our senior management team believe very strongly in Voyant's business model, focused on the intersection of media and technology," said Dana Waldman, Voyant's chief executive officer. The team has deferred a significant fraction of its salary in recent months, and several members are owed various sums for past transactions. "We wanted to demonstrate our belief in the company by personally making these commitments to Voyant."
"These transactions are good for the company because they decrease the liability on our balance sheet and further align the interests of our management with our shareholders," added Chief Financial Officer David R. Wells. "We also feel that they are in our own personal best interests, because we believe that this company, with its compelling vision, technology, connections, products, and know-how, is poised to do very well."
CarBiz Inc. (OTCBB: CBZFF) Up 12.00% on Monday
Detailed quote: http://beaconequityresearch.com/CBZFF
December 17, 2007 - CarBiz's New "Superstore" Expects to Generate Sales Volume Eight Times That of Existing Stores
CarBiz Inc. (OTCBB:CBZFF), the fourth largest Buy Here Pay Here car dealership chain in
The new facility will have the average vehicle price at $15,000 compared to under $6,000 at CarBiz's typical store and overall unit sales are expected to be up to four times that of a typical CarBiz store as well. Contract terms are expected to be up to four years which will further enhance the company's revenue position by maintaining a customer longer and exposing them to other alternative financial services such as pay day loans and check cashing.
Company CEO Mr. Carl Ritter is looking forward to 2008 and this addition to CarBiz's portfolio. He said, "The superstore model is a project that we have been analyzing for some time. We expect it to add significant revenue and earnings to our Buy Here Pay Here division and we hope to add additional superstores in the future."
The
Nutra Pharma Corp. (OTCBB: NPHC) Up 11.54% on Monday
Detailed quote: http://beaconequityresearch.com/NPHC
December 17, 2007 - Nutra Pharma Announces Successful Completion of 6-Month Patient Crossover in AMN Clinical Trial
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that its drug discovery arm, ReceptoPharm, has successfully completed its six-month patient crossover in the Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy (AMN).
The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo. RPI-78M is ReceptoPharm's lead drug candidate for the treatment of neurological and autoimmune disorders.
"This is an important milestone in our clinical development process, as successful completion of this crossover acts as an early indication that our trial is running smoothly," explained Paul Reid, CEO of ReceptoPharm, Inc. "As we move into the second-half of our trial, we will continue to monitor patients closely to determine efficacy of our treatment," he added.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades. AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS). There is currently no approved treatment for AMN. Additionally, the disease's rarity designates it as an orphan drug candidate both in Europe and in the
"We're confident in what we've seen in previous patient trials. But because this is a double-blind, placebo-controlled study, we will not know patient results until the trial is fully-completed," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As the study progresses, we will continue to provide relevant information about this trial to our shareholders and to the public," he concluded.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has not been compensated by any of the companies covered in this release. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
